Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties

E. Potůčková, K. Hrušková, J. Bureš, P. Kovaříková, IA. Špirková, K. Pravdíková, L. Kolbabová, T. Hergeselová, P. Hašková, H. Jansová, M. Macháček, A. Jirkovská, V. Richardson, DJ. Lane, DS. Kalinowski, DR. Richardson, K. Vávrová, T. Šimůnek,

. 2014 ; 9 (11) : e112059. [pub] 20141113

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010697

Salicylaldehyde isonicotinoyl hydrazone (SIH) is a lipophilic, tridentate iron chelator with marked anti-oxidant and modest cytotoxic activity against neoplastic cells. However, it has poor stability in an aqueous environment due to the rapid hydrolysis of its hydrazone bond. In this study, we synthesized a series of new SIH analogs (based on previously described aromatic ketones with improved hydrolytic stability). Their structure-activity relationships were assessed with respect to their stability in plasma, iron chelation efficacy, redox effects and cytotoxic activity against MCF-7 breast adenocarcinoma cells. Furthermore, studies assessed the cytotoxicity of these chelators and their ability to afford protection against hydrogen peroxide-induced oxidative injury in H9c2 cardiomyoblasts. The ligands with a reduced hydrazone bond, or the presence of bulky alkyl substituents near the hydrazone bond, showed severely limited biological activity. The introduction of a bromine substituent increased ligand-induced cytotoxicity to both cancer cells and H9c2 cardiomyoblasts. A similar effect was observed when the phenolic ring was exchanged with pyridine (i.e., changing the ligating site from O, N, O to N, N, O), which led to pro-oxidative effects. In contrast, compounds with long, flexible alkyl chains adjacent to the hydrazone bond exhibited specific cytotoxic effects against MCF-7 breast adenocarcinoma cells and low toxicity against H9c2 cardiomyoblasts. Hence, this study highlights important structure-activity relationships and provides insight into the further development of aroylhydrazone iron chelators with more potent and selective anti-neoplastic effects.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16010697
003      
CZ-PrNML
005      
20170426102624.0
007      
ta
008      
160408s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0112059 $2 doi
024    7_
$a 10.1371/journal.pone.0112059 $2 doi
035    __
$a (PubMed)25393531
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Potůčková, Eliška $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic. $7 xx0153394
245    10
$a Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties / $c E. Potůčková, K. Hrušková, J. Bureš, P. Kovaříková, IA. Špirková, K. Pravdíková, L. Kolbabová, T. Hergeselová, P. Hašková, H. Jansová, M. Macháček, A. Jirkovská, V. Richardson, DJ. Lane, DS. Kalinowski, DR. Richardson, K. Vávrová, T. Šimůnek,
520    9_
$a Salicylaldehyde isonicotinoyl hydrazone (SIH) is a lipophilic, tridentate iron chelator with marked anti-oxidant and modest cytotoxic activity against neoplastic cells. However, it has poor stability in an aqueous environment due to the rapid hydrolysis of its hydrazone bond. In this study, we synthesized a series of new SIH analogs (based on previously described aromatic ketones with improved hydrolytic stability). Their structure-activity relationships were assessed with respect to their stability in plasma, iron chelation efficacy, redox effects and cytotoxic activity against MCF-7 breast adenocarcinoma cells. Furthermore, studies assessed the cytotoxicity of these chelators and their ability to afford protection against hydrogen peroxide-induced oxidative injury in H9c2 cardiomyoblasts. The ligands with a reduced hydrazone bond, or the presence of bulky alkyl substituents near the hydrazone bond, showed severely limited biological activity. The introduction of a bromine substituent increased ligand-induced cytotoxicity to both cancer cells and H9c2 cardiomyoblasts. A similar effect was observed when the phenolic ring was exchanged with pyridine (i.e., changing the ligating site from O, N, O to N, N, O), which led to pro-oxidative effects. In contrast, compounds with long, flexible alkyl chains adjacent to the hydrazone bond exhibited specific cytotoxic effects against MCF-7 breast adenocarcinoma cells and low toxicity against H9c2 cardiomyoblasts. Hence, this study highlights important structure-activity relationships and provides insight into the further development of aroylhydrazone iron chelators with more potent and selective anti-neoplastic effects.
650    _2
$a aldehydy $x chemie $x farmakologie $x toxicita $7 D000447
650    _2
$a protinádorové látky $x chemie $x toxicita $7 D000970
650    _2
$a antioxidancia $x chemie $x farmakologie $7 D000975
650    _2
$a buněčné linie $7 D002460
650    _2
$a lidé $7 D006801
650    _2
$a hydrazony $x chemie $x farmakologie $x toxicita $7 D006835
650    _2
$a peroxid vodíku $x toxicita $7 D006861
650    _2
$a chelátory železa $x chemie $x farmakologie $7 D007502
650    _2
$a MFC-7 buňky $7 D061986
650    _2
$a myoblasty $x účinky léků $7 D032446
650    _2
$a oxidační stres $x účinky léků $7 D018384
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hrušková, Kateřina $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
700    1_
$a Bureš, Jan $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
700    1_
$a Kovaříková, Petra $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
700    1_
$a Špirková, Iva A $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
700    1_
$a Pravdíková, Kateřina $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
700    1_
$a Kolbabová, Lucie $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
700    1_
$a Hergeselová, Tereza $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
700    1_
$a Hašková, Pavlína $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
700    1_
$a Jansová, Hana $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
700    1_
$a Macháček, Miloslav $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
700    1_
$a Jirkovská, Anna $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
700    1_
$a Richardson, Vera $u Molecular Pharmacology and Pathology Program, Bosch Institute and Department of Pathology, University of Sydney, Sydney, Australia.
700    1_
$a Lane, Darius J R $u Molecular Pharmacology and Pathology Program, Bosch Institute and Department of Pathology, University of Sydney, Sydney, Australia.
700    1_
$a Kalinowski, Danuta S $u Molecular Pharmacology and Pathology Program, Bosch Institute and Department of Pathology, University of Sydney, Sydney, Australia.
700    1_
$a Richardson, Des R $u Molecular Pharmacology and Pathology Program, Bosch Institute and Department of Pathology, University of Sydney, Sydney, Australia.
700    1_
$a Vávrová, Kateřina $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
700    1_
$a Šimůnek, Tomáš $u Charles University in Prague, Faculty of Pharmacy in Hradec Králové, Hradec Králové, Czech Republic.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 9, č. 11 (2014), s. e112059
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25393531 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20170426102943 $b ABA008
999    __
$a ok $b bmc $g 1114126 $s 935065
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 9 $c 11 $d e112059 $e 20141113 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...